Table 1.

Baseline characteristics and treatment outcome of TNBC patients treated with neoadjuvant chemotherapy (N = 54)

Age at diagnosis
median (min-max) [IQrange]	49.2 (26.7–76.6) [45.3–60.3]
<49	25 (46.3)
≥49	29 (53.7)
Stage
II	18 (33.3)
III	36 (66.7)
Grade
1–2	22 (40.7)
3	32 (59.3)
Ki-67
median (min-max) [IQrange]	70.0 (10.0–90.0) [43.7–80.0]
Chemotherapy
Sequential	47 (87.0)
Concomitant	7 (13.0)
pCR
No	37 (68.5)
Yes	17 (31.5)
BMI
median (min-max) [IQrange]	23.9 (17.5–41.6) [21.7–25.9]
< 25	31 (57.4)
≥ 25	23 (42.6)
γ-H2AX
Low	25 (46.3)
High	29 (53.7)
pChk1
Neg	16 (29.6)
Pos	38 (70.4)